# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-052940
Filing Date
2023-04-28
Accepted
2023-04-28 16:08:55
Documents
6
Period of Report
2023-08-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm231922-1_def14a.htm | DEF 14A | 975357
2 | GRAPHIC | lg_avadel-4clr.jpg | GRAPHIC | 31027
3 | GRAPHIC | lc_ttlshrholret-4clr.jpg | GRAPHIC | 172763
4 | GRAPHIC | lc_gaapnetinc-4clr.jpg | GRAPHIC | 143701
5 | GRAPHIC | px_avadelproxy1pg1-4clr.jpg | GRAPHIC | 961525
6 | GRAPHIC | px_avadelproxy1pg2-4c.jpg | GRAPHIC | 623522
| Complete submission text file | 0001104659-23-052940.txt |  | 3376288

Mailing Address 16640 CHESTERFIELD GROVE ROAD SUITE 200 CHESTERFIELD MO 63005
Business Address BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN DUBLIN L2 15 636-449-1830
AVADEL PHARMACEUTICALS PLC (Filer) CIK: 0001012477 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37977 | Film No.: 23866093
SIC: 2834 Pharmaceutical Preparations